Assessment of the efficacy, tolerability and pharmaco-economic impact of zoledronic acid treatment in prostate cancer with bone metastasis

Trial Profile

Assessment of the efficacy, tolerability and pharmaco-economic impact of zoledronic acid treatment in prostate cancer with bone metastasis

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Mar 2017

At a glance

  • Drugs Zoledronic acid (Primary)
  • Indications Cancer metastases; Prostate cancer
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 06 Apr 2010 Actual number of patients (148) added and primary outcomes amended as reported by ClinicalTrials.gov record.
    • 06 Apr 2010 Actual end date (1 Jan 2006) added as reported by ClinicalTrials.gov record.
    • 06 Apr 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top